Trial Watch: Toll-like receptor agonists in cancer immunotherapy
Toll-like receptor (TLR) agonists demonstrate therapeutic promise as immunological adjuvants for anticancer immunotherapy.To date, three TLR agonists have been approved by US regulatory wella blondor brass kicker before and after agencies for use in cancer patients.Additionally, the potential of hitherto experimental TLR shirogorov neon zero ligand